01.12.2016

Orale Antikoagulation bei nicht-valvulärem Vorhofflimmern und eingeschränkter Nierenfunktion

Frau hält sich ein Modell einer Niere auf beide Beckenseiten.

© benschonewille / Fotolia

Dialyse und Antikoagulation in Kombination bedeutet für Arzt und Patient eine Herausforderung.

Quellen:

  1. Heidbuchel H et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507.
  2. Fachinformation Marcumar®, MEDA Pharma GmbH & Co. KG, Bad Homburg. Stand Mai 2015.
  3. Salim I et al. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety. Expert Opin Drug Saf 2013; 12: 53-63.
  4. Kruger T et al. Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. Nephrol Dial Transplant 2013; 28: 534-541.
  5. Reinecke H et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-711.
  6. Reinecke H et al. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. Stroke 2013; 44: 2935-2941.
  7. Limdi NA et al. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis 2015; 65: 701-709.
  8. Ahrens I et al. Vorhofflimmern: welches Antikoagulans für welchen Patienten? Aktuelle Kardiologie 2015; 4: 104–109.
  9. Bohula EA et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 2016; 134: 24-36.
  10. Hijazi Z et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2016; 1: 451-460.
  11. Fachinformation Pradaxa®, Böhringer Ingelheim International GmbH, Ingelheim am Rhein. Stand Januar 2016.
  12. Fachinformation Eliquis®, Pfizer Pharma GmbH, Berlin. Stand September 2015.
  13. Fachinformation LIXIANA®, Daiichi Sankyo Europe GmbH, München, Deutschland. Aktueller Stand. http://www.lixiana.de/de-de/fachinformation
  14. Fachinformation Xarelto®, Bayer Pharma AG, Berlin. Stand Juli 2015.
  15. Harmon JP et al. Anticoagulant and antiplatelet therapy in patients with chronic kidney disease: risks versus benefits review. Curr Opin Nephrol Hypertens 2013; 22: 624-628.
  16. Brandenburg VM et al. [Calciphylaxis]. Dtsch Med Wochenschr 2015: 347-351.

INFORMATION FÜR FACHKRÄFTE

[DocCheckStop]